Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $811.57B | 39.4x | 0.42 | $905.03 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.6% Upside | Upgrade to Pro+ | |
| J&J | NYSE | Healthcare | Pharmaceuticals | $578.31B | 27.3x | -7.06 | $238.60 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
| AbbVie | NYSE | Healthcare | Pharmaceuticals | $368.98B | 88.3x | -70.78 | $208.42 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
| Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $335.94B | 19.8x | 0.36 | $50.98 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10% Upside | Upgrade to Pro+ | |
| AstraZeneca | NYSE | Healthcare | Pharmaceuticals | $310.55B | 30.6x | 0.68 | $201.21 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
| Merck&Co | NYSE | Healthcare | Pharmaceuticals | $292.04B | 16.2x | 2.02 | $117.92 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.2% Upside | Upgrade to Pro+ | |
| Novartis | OTC Markets | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $146.25 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $152.06 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.2% Downside | Upgrade to Pro+ | |
| Amgen | NASDAQ | Healthcare | Pharmaceuticals | $188.03B | 24.2x | 0.28 | $348 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0% Upside | Upgrade to Pro+ | |
| Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $176.58B | 11x | 6.03 | $40.81 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
| Gilead | NASDAQ | Healthcare | Pharmaceuticals | $173.65B | 20.4x | 0.01 | $139.77 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
| Pfizer | NYSE | Healthcare | Pharmaceuticals | $154.89B | 19.9x | -5.94 | $27.19 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.8% Upside | Upgrade to Pro+ | |
| Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $118.48B | 16.6x | 0.09 | $57.89 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
| GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $29.24 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $57.81 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
| Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $115.93B | 20.2x | 0.45 | $48.01 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
| Vertex | NASDAQ | Healthcare | Pharmaceuticals | $112.52B | 28.9x | 0.03 | $441.64 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
| McKesson | NYSE | Healthcare | Pharmaceuticals | $105.71B | 24.8x | 0.41 | $863.42 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
| Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $89.54B | 32.8x | 2.67 | $27.20 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron Pharma | NASDAQ | Healthcare | Pharmaceuticals | $77.53B | 18.1x | 2.1 | $753.85 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
| Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $60.15B | 19.5x | -3.18 | $27.62 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
| UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $59.87B | 32.5x | 0.71 | $156.57 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
| Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $56.17B | 80.2x | -1.73 | $34.52 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $56.17B | 80.2x | -1.71 | $17.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $50.70B | 20.1x | 1.89 | $120.76 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
| Cardinal Health | NYSE | Healthcare | Pharmaceuticals | $49.71B | 30.4x | 1.04 | $211.83 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
| CSL | OTC Markets | Healthcare | Pharmaceuticals | $47.94B | 34.9x | -0.68 | $25.40 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
| Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | $47.08B | -11.1x | 0.26 | $11.96 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
| Alnylam | NASDAQ | Healthcare | Pharmaceuticals | $44.25B | 144.1x | 0.69 | $333.27 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.7% Upside | Upgrade to Pro+ | |
| HALEON ADR | NYSE | Healthcare | Pharmaceuticals | $43.19B | 19.7x | 1.07 | $9.66 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
| Sandoz | OTC Markets | Healthcare | Pharmaceuticals | $37.55B | 39.5x | $84.97 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Teva ADR | NYSE | Healthcare | Pharmaceuticals | $36.99B | 25.9x | 0.14 | $31.61 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.9% Upside | Upgrade to Pro+ | |
| Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | $34.96B | 15.4x | 1.89 | $33.27 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.8% Upside | Upgrade to Pro+ | |
| Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | $32.67B | 17.2x | 0.61 | $18.55 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.2% Upside | Upgrade to Pro+ | |
| Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | $29.24B | 14.5x | 0.02 | $16.46 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | $28.04B | 27.3x | -3.97 | $48.71 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.4% Upside | Upgrade to Pro+ | |
| Biogen | NASDAQ | Healthcare | Pharmaceuticals | $26.52B | 20.3x | -0.95 | $180.50 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
| United Therapeutics | NASDAQ | Healthcare | Pharmaceuticals | $25.29B | 19.3x | 1.45 | $577.67 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
| Moderna | NASDAQ | Healthcare | Pharmaceuticals | $21.54B | -7.5x | -0.34 | $54.26 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -23.5% Downside | Upgrade to Pro+ | |
| Roivant Sciences | NASDAQ | Healthcare | Pharmaceuticals | $20.98B | -24.9x | 0.04 | $29.39 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
| Incyte | NASDAQ | Healthcare | Pharmaceuticals | $19.35B | 15.2x | 0 | $97.10 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
| Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | $17.80B | 14.4x | 0.93 | $10.40 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
| Viatris | NASDAQ | Healthcare | Pharmaceuticals | $16.22B | -4.7x | 0.01 | $13.86 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
| Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | $15.90B | 30.9x | 1.08 | $49.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Swedish Orphan Biovitrum AB ADR | OTC Markets | Healthcare | Pharmaceuticals | $15.57B | 300.6x | -1.8 | $20.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| BridgeBio Pharma | NASDAQ | Healthcare | Pharmaceuticals | $15.04B | -20.3x | 0.66 | $77.70 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
| CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | $13.78B | 24.1x | -2.97 | $1.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Neurocrine | NASDAQ | Healthcare | Pharmaceuticals | $13.22B | 28.2x | 0.65 | $131.44 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.4% Upside | Upgrade to Pro+ | |
| Jazz Pharma | NASDAQ | Healthcare | Pharmaceuticals | $12.33B | -34.3x | 0.21 | $199.23 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.4% Upside | Upgrade to Pro+ | |
| Orion ADR | OTC Markets | Healthcare | Pharmaceuticals | $12.17B | 20.6x | 0.4 | $37.99 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |